Drug trial aims to hold off devastating blood cancer
NCT ID NCT05014646
Summary
This study is testing whether a drug called leflunomide can delay or prevent high-risk smoldering myeloma from turning into active multiple myeloma. It involves 27 adults who identify as African-American or European-American and have high-risk smoldering myeloma. Participants take a daily pill and are monitored to see if the treatment slows disease progression and is safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atrium Health University City/LCI-University
Charlotte, North Carolina, 28204, United States
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.